Back to News
Market Impact: 0.35
Enlivex Reports 79% Response Rate With Allocetra In Older Knee OA Patients
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Enlivex Therapeutics announced positive 12-month topline results from the Phase IIa stage of its Phase I/IIa trial evaluating Allocetra. The article text is truncated before completing the patient description and provides no numerical efficacy or safety results, so the magnitude of the findings cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ENLV0.70
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead